02/04/2026
Why I have a low threshold to treat androgenic alopecia? Hint… It's not for the looks
I love preventative care. I really appreciate the concept of preventing a disease from ever occurring. It’s not sexy medicine, it's often non-invasive and relies on people skills rather than procedural skills. It is also often the lowest cost, lowest risk, and highest reward when it comes to healthcare outcomes.
I like to think of myself as a true generalist with a broad patient cohort, but being a male GP Reg, invariably I do my fair share of men’s health.
When I first started community practice, I would only really engage in hair loss prevention when actively being sought by a patient, but working in Queensland, Australia, means daily engagement with skin cancer, and I soon saw an obvious but unappreciated link.
I very rapidly noted a concerning proportion of my balding male patients were reporting incidental skin lesions on their scalps. This was something that was comparatively rare in my female cohort, and when occurring, it was specific to the hair part line.
Now this is simply common sense, men get bald faster, lose their sun protection and develop skin cancers of the scalp, ears and face at a higher rate, but the data also backs up what I was seeing regarding this. Studies such as Li et al. (2016, International Journal of Cancer) have linked male pattern baldness to increased rates of skin cancers and AIHW data identifies higher rates of head and scalp cancers in men.
Evidence on a direct link between androgenic alopecia treatment and scalp, face, and ear skin cancer reduction is almost absent. Despite this, I feel that on face value, it passes the pub test enough for me to advocate for at least the less intensive methods, while waiting for the research to fill this gap.
As with any therapy, I discuss the potential risks and side effects, as well as the evidence (or currently limited evidence) behind the treatment. Cost and administration burden are also factors to consider; however, I feel it is reasonable to initiate a pragmatic discussion around hair loss prevention to reduce UV scalp exposure, given my high skin cancer risk patient cohort.
For patients for whom I have noted their hair loss, rather than them actively presenting for that purpose, I generally limit my management to topical minoxidil +/- microneedling. I feel this is a reasonable balance between treatment burden and benefit, but this is a patient-by-patient discussion, as with any therapy.
Of course, I ensure never to neglect my advocacy for balding patients to ensure they slip slop slap, but working to maintain their all-day hair hat has become an adjunctive treatment.
While I look forward to research either proving me right or wrong, my clinical judgment and what limited evidence is available tell me early intervention of androgenic alopecia will one day be part of our skin cancer prevention strategies in general practice.
(This post was not written by AI)
